文献速递慢性肾脏病

芬兰3-4期慢性肾脏病合并与不合并2型糖尿病的特征、治疗与疾病负担

Characteristics, treatment and disease burden among stage 3-4 chronic kidney disease patients with and without type 2 diabetes in Finland during 2016-2022.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该队列研究利用芬兰五个市镇初级与医院诊疗数据,识别2016年起确诊的3-4期慢性肾脏病患者并随访至2022年底,按是否合并2型糖尿病分层分析。结果显示3-4期慢性肾脏病患病率为6.3%,多数患者不合并2型糖尿病,其白蛋白尿筛查与肾脏保护治疗使用率更低,但一年死亡风险与合并糖尿病者相近。

要点

  • 3-4期慢性肾脏病患病率为6.3%,多数患者不合并2型糖尿病。
  • 不合并2型糖尿病者基线白蛋白尿筛查率9%、肾脏保护治疗使用率47%,均低于合并糖尿病者。
  • 无论是否合并2型糖尿病,1年内约10%患者死亡,医疗资源利用高。

核心结论

  • 芬兰3-4期慢性肾脏病患病率高,白蛋白尿检测与肾脏保护药物使用不足,不合并2型糖尿病者预防管理更薄弱但风险相近。
  • 研究呼吁尤其针对不合并2型糖尿病的慢性肾脏病患者提高疾病意识与风险管理。

研究设计与样本

  • 基于芬兰五个市镇初级与医院诊疗数据的队列研究,纳入2016年起符合3-4期慢性肾脏病标准的成人患者。
  • 3-4期慢性肾脏病定义为一次eGFR 15-59 mL/min/1.73 m2且≥90天后再次测量符合,或有登记的慢性肾脏病诊断。
  • 患病率按2022年12月31日确定;共纳入12 474例新发3-4期慢性肾脏病患者,随访至死亡或2022年12月31日,按2型糖尿病状态分析。

主要发现

  • 3-4期慢性肾脏病患病率为6.3%。
  • 12 474例新发患者中73%不合并2型糖尿病,两亚组中位年龄相似。
  • 基线白蛋白尿筛查率在不合并2型糖尿病者为9%、合并2型糖尿病者为53%。
  • 基线肾脏保护治疗使用率在不合并2型糖尿病者为47%、合并2型糖尿病者为69%,且指数后12个月内无变化。
  • 医疗资源利用高,慢性肾脏病或心力衰竭对全因医疗费用的贡献明显大于动脉粥样硬化性疾病,与2型糖尿病状态无关;两亚组1年内均有10%死亡。

关键数值与推荐

  • 3-4期慢性肾脏病诊断标准:一次eGFR 15-59 mL/min/1.73 m2且≥90天后再次测量符合,或有登记的慢性肾脏病诊断。
  • 患病率判定日期为2022年12月31日,新发队列自2016年1月1日起首次符合标准之日为指数日期。

临床怎么用

  • 对3-4期慢性肾脏病患者应加强白蛋白尿筛查与肾脏保护治疗,尤其关注不合并2型糖尿病者。
  • 慢性肾脏病与心力衰竭是全因医疗费用的主要贡献因素,管理时应重视其经济负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world evidence on the management of chronic kidney disease (CKD) with and without type 2 diabetes (T2D) is limited. This study described the characteristics, treatment and disease burden in patients with stage 3-4 CKD with and without T2D in Finland. METHODS: This cohort study used data from primary and hospital care in five municipalities in Finland to identify adults with stage 3-4 CKD, defined as having either one estimated glomerular filtration rate (eGFR) measurement of 15-59 mL/min/1.73 m2 followed by a second measurement taken ≥90 days later, or a registered CKD diagnosis. Prevalence was determined on 31 December 2022, and a cohort of incident stage 3-4 CKD patients was followed from the first date fulfilling eligibility criteria since 1 January 2016 (index) until death or 31 December 2022, and analyzed by T2D status. RESULTS: The prevalence of stage 3-4 CKD was 6.3%. Among the 12 474 incident stage 3-4 CKD patients, the majority were non-T2D (73%). The median age was similar for non-T2D and T2D CKD patients, respectively. Baseline albuminuria screening was 9% among non-T2D and 53% among T2D. The use of kidney-protective treatments at index was also lower in non-T2D patients (47%), compared with T2D patients (69%). The use of kidney-protective treatments remained unchanged during 12 months after index. Healthcare resource utilization was high, and CKD or heart failure contributed considerably more to the all-cause healthcare costs than atherosclerotic diseases, regardless of T2D status. In both CKD subgroups, 10% had died within 1 year. CONCLUSIONS: In Finland, CKD is highly prevalent and associated with high risks and low use of albuminuria testing and kidney-protective medications. Most CKD patients were non-T2D, which showed lower use of preventive management and similar risks compared with T2D patients. These findings call for an urgent need for improved awareness and risk management, especially in non-T2D CKD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Metsärinne K, Bodegård J, Toppila I, et al. Characteristics, treatment and disease burden among stage 3-4 chronic kidney disease patients with and without type 2 diabetes in Finland during 2016-2022. Nephrol Dial Transplant. 2025. PMID: 39510970. doi:10.1093/ndt/gfae242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。